QUESTIONS ABOUT THE GENETIC AND EPIGENETIC MECHANISMS OF UTERINE SARCOMA DEVELOPMENT

Uterine sarcomas are rare and highly aggressive malignant tumors of the female reproductive system characterized by significant histological diversity and poor prognosis. Their low incidence complicates the development of unified diagnostic and treatment approaches. The stage of the disease remains the most important prognostic factor, which led to the introduction of the specialized FIGO staging system. Modern molecular diagnostic methods, including NGS, CGH, FISH, and immunohistochemistry, make it possible to identify genetic alterations underlying tumor transformation. This expands the possibilities for early diagnosis, differential assessment, and personalized treatment of patients with uterine sarcomas.